Aminobenzenesulfonic auristatin E (TFA)

• UNSPSC Description:

  Aminobenzenesulfonic auristatin E TFA is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E TFA has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic[1].

• Target Antigen:

  Drug-Linker Conjugates for ADC; Microtubule/Tubulin

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/aminobenzenesulfonic-auristatin-e-tfa.html

• Solubility:

  DMSO : 330 mg/mL (ultrasonic;warming)

• Smiles:

  C[C@@H](C(N[S](=O)(C(C=C1)=CC=C1N)=O)=O)[C@H]([C@@](CCC2)([H])N2C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@@H](N(C)C)C(C)C)=O)=O)=O)OC.O=C(O)C(F)(F)F

• Molecular Weight:

  867.03

• References & Citations:

  [1]Kevin HAMBLETT, et al. Anti-her2 biparatopic antibody-drug conjugates and methods of use.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported